Loxo Oncology Inc (LOXO) VP Jennifer Burstein Sells 1,500 Shares

Loxo Oncology Inc (NASDAQ:LOXO) VP Jennifer Burstein sold 1,500 shares of the company’s stock in a transaction on Monday, July 9th. The shares were sold at an average price of $187.25, for a total value of $280,875.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jennifer Burstein also recently made the following trade(s):

  • On Tuesday, June 19th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $176.99, for a total value of $300,883.00.
  • On Tuesday, April 24th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $131.65, for a total value of $223,805.00.

Loxo Oncology traded up $5.07, hitting $181.06, during trading hours on Wednesday, MarketBeat Ratings reports. 620,100 shares of the company’s stock traded hands, compared to its average volume of 472,329. The firm has a market capitalization of $5.62 billion, a price-to-earnings ratio of -34.02 and a beta of 2.45. Loxo Oncology Inc has a twelve month low of $69.00 and a twelve month high of $208.95.

Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. The business had revenue of $38.43 million for the quarter, compared to analyst estimates of $12.72 million. During the same period in the previous year, the firm posted ($0.96) earnings per share. sell-side analysts anticipate that Loxo Oncology Inc will post 0.91 earnings per share for the current year.

A number of brokerages have recently issued reports on LOXO. Zacks Investment Research lowered Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Wednesday, April 25th. Citigroup boosted their target price on Loxo Oncology to $235.00 and gave the stock a “buy” rating in a research report on Monday, June 4th. JMP Securities set a $182.00 target price on Loxo Oncology and gave the stock a “buy” rating in a research report on Thursday, May 17th. Piper Jaffray Companies started coverage on Loxo Oncology in a research report on Wednesday, May 30th. They set an “overweight” rating and a $200.00 target price on the stock. Finally, Ifs Securities lowered Loxo Oncology from a “strong-buy” rating to a “market perform” rating in a research report on Monday, June 4th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $176.40.

A number of hedge funds have recently modified their holdings of the business. Lord Abbett & CO. LLC boosted its stake in shares of Loxo Oncology by 20.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 666,771 shares of the biopharmaceutical company’s stock worth $76,926,000 after acquiring an additional 114,963 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Loxo Oncology by 27.3% during the 4th quarter. Franklin Resources Inc. now owns 494,101 shares of the biopharmaceutical company’s stock worth $41,594,000 after acquiring an additional 106,001 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in shares of Loxo Oncology by 2.1% during the 1st quarter. Rock Springs Capital Management LP now owns 316,500 shares of the biopharmaceutical company’s stock worth $36,515,000 after acquiring an additional 6,500 shares in the last quarter. Opaleye Management Inc. boosted its stake in shares of Loxo Oncology by 1.8% during the 1st quarter. Opaleye Management Inc. now owns 179,400 shares of the biopharmaceutical company’s stock worth $20,697,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Loxo Oncology by 2.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 110,975 shares of the biopharmaceutical company’s stock worth $12,804,000 after acquiring an additional 2,960 shares in the last quarter.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply